For: | Magkou D, Tziomalos K. Antidiabetic treatment, stroke severity and outcome. World J Diabetes 2014; 5(2): 84-88 [PMID: 24748923 DOI: 10.4239/wjd.v5.i2.84] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v5/i2/84.htm |
Number | Citing Articles |
1 |
L. Castilla-Guerra, M.C. Fernández-Moreno, J. Hewitt. Tratamiento de la hiperglucemia en pacientes con ictus agudo. Revista Clínica Española 2016; 216(2): 92 doi: 10.1016/j.rce.2015.06.005
|
2 |
Fu-Shun Yen, Jen-Huai Chiang, Chun-Wei Pan, Boniface J. Lin, James Cheng-Chung Wei, Chih-Cheng Hsu. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy. Diabetes Research and Clinical Practice 2018; 140: 279 doi: 10.1016/j.diabres.2018.04.012
|
3 |
Suehyun Lee, Seongwoo Jeon, Hun-Sung Kim. A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus. Endocrinology and Metabolism 2022; 37(2): 195 doi: 10.3803/EnM.2022.1404
|
4 |
Maryam A. Salaudeen, Nura Bello, Rabiu N. Danraka, Maryam L. Ammani. Understanding the Pathophysiology of Ischemic Stroke: The Basis of Current Therapies and Opportunity for New Ones. Biomolecules 2024; 14(3): 305 doi: 10.3390/biom14030305
|
5 |
Vishal Chavda, Snehal Patel. Hyperglycaemic Metabolic Complications of Ischemic Brain: Current
Therapeutics, Anti-Diabetics and Stem Cell Therapy. CNS & Neurological Disorders - Drug Targets 2023; 22(6): 832 doi: 10.2174/1871527321666220609200852
|
6 |
Jia Guo, Hailan Wang, Xin Jiang, Yan Wang, Zhihao Zhang, Qingbin Liao, Jia Xu, Xiaohan Ren. An Untargeted Lipidomics Study of Acute Ischemic Stroke with Hyperglycemia Based on Ultrahigh-Performance Liquid Chromatography-Mass Spectrometry. Computational and Mathematical Methods in Medicine 2022; 2022: 1 doi: 10.1155/2022/8332278
|
7 |
Konstantinos Tziomalos, Panagiotis Dimitriou, Stella D. Bouziana, Marianna Spanou, Stavroula Kostaki, Stella-Maria Angelopoulou, Maria Papadopoulou, Vasilios Giampatzis, Christos Savopoulos, Apostolos I. Hatzitolios. Stress hyperglycemia and acute ischemic stroke in-hospital outcome. Metabolism 2017; 67: 99 doi: 10.1016/j.metabol.2016.11.011
|
8 |
Konstantinos Tziomalos, Stella D Bouziana, Marianna Spanou, Stavroula Kostaki, Maria Papadopoulou, Vasilios Giampatzis, Vasiliki Dourliou, Danai-Thomais Kostourou, Christos Savopoulos, Apostolos I Hatzitolios. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke. Diabetes and Vascular Disease Research 2015; 12(6): 463 doi: 10.1177/1479164115597867
|
9 |
Vladimer Darsalia, Thomas Klein, Thomas Nyström, Cesare Patrone. Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology 2018; 136: 280 doi: 10.1016/j.neuropharm.2017.08.022
|
10 |
L. Castilla-Guerra, M.C. Fernández-Moreno, J. Hewitt. Treatment of hyperglycemia in patients with acute stroke. Revista Clínica Española (English Edition) 2016; 216(2): 92 doi: 10.1016/j.rceng.2015.08.002
|
11 |
Olaf Eberhardt, Helge Topka. Neurological outcomes of antidiabetic therapy: What the neurologist should know. Clinical Neurology and Neurosurgery 2017; 158: 60 doi: 10.1016/j.clineuro.2017.04.014
|
12 |
Yohei Mima, Takahiro Kuwashiro, Masahiro Yasaka, Yuichiro Tsurusaki, Asako Nakamura, Yoshiyuki Wakugawa, Yasushi Okada. Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. Journal of Stroke and Cerebrovascular Diseases 2016; 25(2): 436 doi: 10.1016/j.jstrokecerebrovasdis.2015.10.016
|
13 |
Debarati Ghosh, Karan Sehgal, Babasaheb Sodnar, Nikhil Bhosale, Deepaneeta Sarmah, Aishika Datta, Antra Chaudhary, Kiran Kalia, Xin Wang, Pallab Bhattacharya. Drug repurposing for stroke intervention. Drug Discovery Today 2022; 27(7): 1974 doi: 10.1016/j.drudis.2022.03.003
|
14 |
Gang Zhang, Samuel Kim, Xiaohuan Gu, Shan Ping Yu, Ling Wei. DPP-4 Inhibitor Linagliptin is Neuroprotective in Hyperglycemic Mice with Stroke via the AKT/mTOR Pathway and Anti-apoptotic Effects. Neuroscience Bulletin 2020; 36(4): 407 doi: 10.1007/s12264-019-00446-w
|
15 |
Vladimer Darsalia, Martin Larsson, David Nathanson, Thomas Klein, Thomas Nyström, Cesare Patrone. Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke. Journal of Cerebral Blood Flow & Metabolism 2015; 35(5): 718 doi: 10.1038/jcbfm.2015.17
|
16 |
Vishal Chavda, Bipin Chaurasia, Harsh Deora, Giuseppe Emmanuele Umana. Chronic Kidney disease and stroke: A Bi-directional risk cascade and therapeutic update. Brain Disorders 2021; 3: 100017 doi: 10.1016/j.dscb.2021.100017
|
17 |
Kazo Kanazawa, Nobukazu Miyamoto, Kenichiro Hira, Chikage Kijima, Yuji Ueno, Nobutaka Hattori. Baseline platelet count may predict short-term functional outcome of cerebral infarction. BMC Neurology 2022; 22(1) doi: 10.1186/s12883-022-02845-5
|
18 |
Francesco Paneni, Francesco Cosentino. Diabetes and Cardiovascular Disease. 2015; : 189 doi: 10.1007/978-3-319-17762-5_15
|
19 |
F. Barkas, M. Elisaf, V. Tsimihodimos, H. Milionis. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. Diabetes & Metabolism 2017; 43(1): 1 doi: 10.1016/j.diabet.2016.10.006
|
20 |
Isaac Arbeláez-Quintero, Mauricio Palacios. To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents. Stroke Research and Treatment 2017; 2017: 1 doi: 10.1155/2017/9756429
|